Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Verona Pharma PLC ADR
VRNACurrent price
66.78 USD
+1.27 USD (+1.94%)
Last closed
66.81 USD
Company
www.veronapharma.com
ISIN
US9250501064
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 492 555 520 USD
Yield for 12 month
+325.08 %
1Y
3Y
5Y
10Y
15Y
VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Address: 3 More London Riverside, London, United Kingdom, SE1 2RE
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
47.29 USDP/E ratio
–Dividend Yield
–Current Year
+458 000 USD
Last Year
+458 000 USD
Current Quarter
+5 624 000 USD
Last Quarter
–
Current Year
-679 624 USD
Last Year
+112 000 USD
Current Quarter
+5 081 000 USD
Last Quarter
-270 302 USD
Key Figures VRNA
1 year
3 years
5 years
10 years
EBITDA
-150 296 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-28.05 %
PEG Ratio
–
Return On Equity TTM
-78.03 %
Wall Street Target Price
47.29 USD
Revenue TTM
5 624 000 USD
Book Value
1.60 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
112 000 USD
Earnings per share
-2.00 USD
Diluted Eps TTM
-2.00 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics VRNA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History VRNA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation VRNA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
583.01
Price Sales TTM
621.01
Enterprise Value EBITDA
-20.89
Price Book MRQ
26.76
Financials VRNA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators VRNA
For 52 weeks
11.39 USD
43.73 USD
50 Day MA
36.60 USD
Shares Short Prior Month
5 976 933
200 Day MA
23.69 USD
Short Ratio
5.44
Shares Short
6 356 902
Short Percent
8.11 %
BeatStart